Literature DB >> 21861221

Focused ultrasound ablation for the treatment of breast cancer.

David R Brenin1.   

Abstract

Advances in technology and changes in our understanding of tumor biology have allowed breast cancer treatment to evolve toward less disfiguring procedures. Noninvasive ablative therapy is a natural continuation of this trend. The following paper presents the concepts underpinning focused ultrasound ablation therapy for the treatment of breast cancer and reviews the investigative experience to date in the evaluation of this promising technique.

Entities:  

Mesh：

Year:  2011        PMID： 21861221     DOI： 10.1245/s10434-011-2011-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


  5 in total

Review 1.  MR-guided focused ultrasound surgery, present and future.

Authors:  David Schlesinger; Stanley Benedict; Chris Diederich; Wladyslaw Gedroyc; Alexander Klibanov; James Larner
Journal:  Med Phys       Date:  2013-08       Impact factor: 4.071

2.  Magnetic resonance-guided focused ultrasound treatment of facet joint pain: summary of preclinical phase.

Authors:  Sagi Harnof; Zion Zibly; Lilach Shay; Osnat Dogadkin; Arik Hanannel; Yael Inbar; Itay Goor-Aryeh; Israel Caspi
Journal:  J Ther Ultrasound       Date:  2014-02-28

Review 3.  Perspectives on Recent Progress in Focused Ultrasound Immunotherapy.

Authors:  Natasha D Sheybani; Richard J Price
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

4.  Experimental validation of acoustic and thermal modeling in heterogeneous phantoms using the hybrid angular spectrum method.

Authors:  Megan Hansen; Douglas Christensen; Allison Payne
Journal:  Int J Hyperthermia       Date:  2021       Impact factor: 3.914

Review 5.  Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier.

Authors:  Andrew M Hersh; Meghana Bhimreddy; Carly Weber-Levine; Kelly Jiang; Safwan Alomari; Nicholas Theodore; Amir Manbachi; Betty M Tyler
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.